NCT00996710
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation

Drug Category: Other

Key Eligibility Criteria:

Gender: Other
Age: Other
Location of Metastases: 
Additional Notes: Patients must have been diagnosed with breast cancer at or under the age of 45
Exclusions: Patients with or a family history of a known genetic mutation that is indicative of hereditary cancer susceptibility (e.g. BRCA, CHEK, MLH, MSH, PMS, TP53, etc.)
https://ClinicalTrials.gov/show/NCT00996710